First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of ...

Researchers from the USC Norris Comprehensive Cancer Center and collaborators report that they have found evidence that targeting CD47, a protein that is part of the innate immune system, could be a ...

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "CD47 Inhibitors Drug Market Opportunity, Clinical Application by Indications & Clinical Trials Insight 2026" report has been added to ...

CD47-directed therapies offer a novel immuno-oncology strategy for engaging the innate immune system in a variety of tumor types. Early results provide a rationale for expanding trials with promising ...

In a further sign of growing interest among large drugmakers in an emerging target for cancer immunotherapy drugs, a company in the space is getting an equity investment from one of the world’s ...

Traditionally, cancer management has primarily relied on surgery, radiation therapy, and chemotherapy. While these treatments have demonstrated significant efficacy in eradicating primary tumors, they ...

Bone fracture healing is a highly coordinated process involving inflammation, fibrovascular formation, and mineralization. Vascularization plays a pivotal role, as inadequate blood supply can severely ...

Phagocytosis relies on a balance between prophagocytic (“eat me”) and antiphagocytic (“don't eat me”) signals on target cells 1,2,3. CD47, initially observed on stem cells, is a transmembrane protein ...